Forma Life Sciences is an operator-owned CDMO focused on providing integrated development and manufacturing services for oral solid dosage medicines. Headquartered in Irvine, California, the company operates two cGMP-compliant facilities that collectively span more than 100,000 square feet and include multiple GMP manufacturing suites designed to support clinical and commercial drug product production.

The company was established following the acquisition of the U.S. drug product development and manufacturing operations of BioDuro by BioSelective Capital Investments. These facilities have an established regulatory track record supporting oral solid dosage programmes across clinical and commercial stages.

Forma’s platform is designed to support pharmaceutical and biotechnology partners across the full product lifecycle, from early formulation development through to large-scale commercial supply. Its manufacturing infrastructure is capable of producing more than two billion tablets and capsules annually, positioning the company as a domestic manufacturing partner for companies seeking U.S.-based development and production capacity.

Key Products and Services

• Oral solid dosage formulation development for tablets and capsules
• Clinical manufacturing services supporting Phase I–III development programmes
• Process scale-up and technical transfer for advancing drug products towards commercial production
• Commercial drug product manufacturing for tablets and capsules
• Spray-dried dispersion development for amorphous solid dispersion systems
• Fluid bed granulation and coating technologies for modified-release and multiparticulate dosage forms
• Controlled- and delayed-release dosage form development using matrix-based technologies

Forma Life Sciences positions itself as a focused U.S. CDMO platform dedicated to oral solid dosage medicines, combining established manufacturing infrastructure with formulation and process development expertise. By integrating development and commercial manufacturing capabilities within a single platform, the company aims to support pharmaceutical and biotechnology partners seeking reliable domestic contract development and manufacturing services throughout the product lifecycle.